Straumann Group reported first-half 2026 revenue of CHF 1.4 billion, 7.8% organic growth, and Q2 revenue of CHF 707.0 million. The company stated iEXCEL drove market share gains in premium implantology and Neodent expanded its geographic reach.
Companies
The Aspen Group launched patient apps for Aspen Dental and ClearChoice Dental Implant Center. The apps cover booking through treatment.
The Aspen Group announced ClearChoice centers will join its November 7, 2026 Day of Service for the first time, donating up to $1 million in full-arch treatment. In 21 markets, an Aspen Dental doctor refers one veteran for evaluation, and clinically appropriate fixed full-arch treatment is provided at no cost.
MegaGen introduced the BLUEDIAMOND ZYGOMA implant system to the U.S. market at its North America Scientific Meeting in Chicago, September 18 to 19, 2026, after FDA clearance in June 2026. The system is for patients with severe maxillary atrophy and supports immediate and delayed loading.
Xtant Medical named BioHorizons, a Henry Schein subsidiary, exclusive distributor of its OsteoFactor Pro allogeneic growth factor in the U.S. and Canadian dental and oral-maxillofacial markets. BioHorizons sells the product as Prolifica.
Straumann Group appointed Christopher Norbye as Chief Executive Officer effective December 1, 2026. He succeeds Guillaume Daniellot, who is stepping down after almost 20 years with the company, seven as CEO.
BIOLASE and MegaGen America announced a U.S. commercial collaboration after their integration, covering customer support, product development and clinical services.
Featured
Featured doctors advertise with the publisher. Featured placement does not change a score or a rank. Disclosure
Periodontist · Sarasota
ICOI Fellow, ICOI Diplomate · AAP member
Featured doctorDr. Michael Pawlus · Sarasota›